Profile: Bristol-Myers Squibb Co (BMY.N)
13 Jan 2017
Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
The Company's late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac. Beclabuvir is an oral small molecule non-nucleoside nonstructural protein 5B (NS5B) inhibitor. BMS-663068 is an investigational compound being studied in HIV-1, which has shown antiviral activity in HIV-1 infected individuals. BMS-663068 is a prodrug, which is metabolized to the active basic compound. Prostvac is Bavarian Nordic's investigational Phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The Company holds rights to develop HuMax-IL8 antibody program and the product candidate HuMax-IL8, a Phase I/II monoclonal antibody targeted against interleukin-8 (IL-8) that represents a potentially complementary immuno-oncology mechanism of action to thymus (T)-cell directed antibodies and co-stimulatory molecules.
The Company's Baraclude is a selective inhibitor of hepatitis B virus. Baraclude is approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus infection.
Hepatitis C Franchise
The Company's Daklinza (daclatasvir (DCV)) is an oral small molecule nonstructural protein 5A (NS5A) replication complex inhibitor for the treatment of hepatitis C virus infection (HCV) and is approved by the FDA for use with Gilead Sciences, Inc.'s (Gilead) sofosbuvir for genotype 3. Sunvepra (asunaprevir (ASV)) is an oral small molecule NS3 protease inhibitor for the treatment of HCV.
The Company's Reyataz is a protease inhibitor for the treatment of HIV. The Reyataz Franchise includes Reyataz and combination therapy Evotaz (atazanavir 300 milligram (mg) and cobicistat 150 mg), a once-daily single tablet two drug regimen combining Reyataz and Gilead's Tybost (cobicistat) for the treatment of HIV-1 infection in adults.
The Company's Sustiva is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV. The Sustiva Franchise includes Sustiva, an antiretroviral drug used in the treatment of HIV, as well as bulk efavirenz, which is included in the combination therapy Atripla (efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg), a once-daily single tablet three-drug regimen combining its Sustiva and Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate).
The Company's Empliciti is a humanized monoclonal antibody, which is approved by the FDA as a treatment for multiple myeloma. Empliciti is approved for the treatment of multiple myeloma as combination therapy with Revlimid and dexamethasone in patients having received one to three prior therapies.
The Company's Erbitux, a biological product, is an Immunoglobulin G (IgG1) monoclonal antibody, which is designed to target and block the Epidermal Growth Factor Receptor (EGFR). Erbitux is approved in combination with irinotecan for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) with failed irinotecan-based regimen and as monotherapy for patients having intolerant of irinotecan. The FDA approved Erbitux for use in combination with radiation therapy, for the treatment of locally or regionally squamous cell carcinoma of the head and neck and, as a single agent, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for patients' prior platinum-based therapy, which has failed. The FDA has also approved Erbitux for the patients first-line recurrent locoregional or metastatic head and neck cancer in combination with platinum-based chemotherapy with 5-Fluorouracil.
The Company's Opdivo, a biological product, is a human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) on T and natural killer T (NKT) cells. The FDA has approved Opdivo for previously untreated patients with metastatic melanoma, previously treated patients with advanced renal cell carcinoma, and previously treated non-squamous (NSQ) and squamous (SQ) non-small cell lung cancer (NSCLC). Its Opdivo received an approval in the European Union for previously treated SQ NSCLC and first-line, and previously treated unresectable or metastatic melanoma. The Opdivo+Yervoy (ipilimumab) regimen is also approved by the FDA for the treatment of BRAF V600 wild-type unresectable or metastatic melanoma. There are various other ongoing registrational trials for Opdivo in head and neck cancer, hodgkin and non-hodgkin lymphoma and bladder cancer, among other tumor types.
The Company's Sprycel is a multi-targeted tyrosine kinase inhibitor approved for the first-line treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Sprycel is also approved for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy, including Gleevec (imatinib mesylate).
The Company's Yervoy, a biological product, is a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma. Yervoy is approved in the United States, the European Union and Japan. The FDA has approved Yervoy for the adjuvant treatment of patients with cutaneous melanoma.
The Company's Abilify is an atypical antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder and major depressive disorder. Abilify also has pediatric uses in schizophrenia and bipolar disorder, among others.
The Company's Orencia, a biological product, is a fusion protein with immunosuppressive activity targeted initially at adult patients with moderately to various active rheumatoid arthritis (RA). Orencia is available in both an intravenous and subcutaneous formulation in the United States, Europe and Japan.
The Company's Eliquis is an oral Factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Eliquis is also targeted for prevention and treatment of venous thromboembolic (VTE) disorders.
Bristol-Myers Squibb Co
345 PARK AVE
NEW YORK NY 10154
Company Web Links
- BRIEF-Bristol-Myers sees operating expenses flat through 2020
- BRIEF-Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb
- BRIEF-Bristol-Myers Squibb and genecentric diagnostics announces exploratory biomarker research collaboration
- Deutsche Bank to pay $95 million to end U.S. tax fraud case
- Ono warns on profit after government halves price of cancer drug Opdivo